Project Grant R43CA275410
Award Date
9/12/23
Completion Date
8/31/24
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,835 to Cambium Oncology LLC to develop a novel CAR-T immunotherapeutic for the treatment of pancreatic cancer. The key products to be delivered include: Engineering CAR-T cells that target the MUC16 antigen and secrete a VIP receptor antagonist (ANT308-FC) to disrupt the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC). This aims to enhance the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $677,176 to The Research Foundation For The State University Of New York (RF SUNY) to advance the development of interstitial chemophototherapy (I-CPT) as a novel treatment approach for locally advanced pancreatic cancer (PACA). The key products and services to be delivered under this 4-year award include: Defining optimal I-CPT light dosimetry for treating large PACA tumors...
The National Cancer Institute awarded Oncotrap Inc. a $400,000 Project Grant to develop an aptamer-directed IgG1-Fc drug conjugate (AFDC) platform for the treatment of pancreatic ductal adenocarcinoma (PDAC). The project aims to validate the ability of the APTPDAC aptamer to selectively kill PDAC cells and create a potent AFDC targeting PDAC cells. Additionally, the project will evaluate the in vivo anti-tumor efficacy of the AFDC in PDAC mouse models and identify the target cell surface...
The National Cancer Institute (NCI) awarded Oncotab, Inc. a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop an optimized targeted radiotherapy for pancreatic ductal adenocarcinoma (PDAC). Oncotab, Inc. will conduct a structured design of experiments to evaluate the use of a humanized tumor-associated MUC1 (TMUC1) antibody, as well as a tandem single-chain variable fragment (scFv) construct, labeled with alpha and beta particle-emitting radioisotopes....
This federal Project Grant award of $269,280 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to determine the biological effects and antitumor activity of a senescent cell-targeted antibody, SIWA318, in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The research aims to evaluate whether depletion of senescent and pro-fibrotic cells in the PDAC tumor microenvironment can improve the efficacy of standard-of-care...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $338,828 to Bioplatinum Technologies LLC to study the effects of new platinum anticancer drugs in pancreatic cancer. The project aims to exploit the high levels of chondroitin-4-sulfate (C4S) glycosaminoglycans in pancreatic tumors to enhance the delivery and efficacy of the polynuclear platinum complex (PPC) drug triplatin. The research will evaluate triplatin as a potential...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,970 to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle formulation designed to improve the delivery and efficacy of combination chemotherapy for advanced pancreatic cancer. The key product being developed under this award is DUO-207, which combines a polymer-conjugated gemcitabine and paclitaxel in a single 14nm nanoparticle. This novel formulation...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $778,873 to Cold Spring Harbor Laboratory (CSHL) to investigate the role of the SOAT1 enzyme as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC). The key objectives are to: 1) Use genetically engineered mouse models to test the effects of SOAT1 deletion on PDAC development and metastasis, and characterize the metabolic impacts; 2) Develop first-in-class small...
The National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $398,398 Cooperative Agreement to Cold Spring Harbor Laboratory (CSHL) to discover natural products and natural product derivatives as inhibitors of KLK6 to prevent the progression of preneoplastic ductal pancreatic cancer. The 3-year award, starting July 2025, aims to: 1) perform pseudo-evolution of natural product libraries using SuFEx click chemistry to enhance efficacy and...